Tetraphase Pharmaceuticals was founded in 2006 and is headquartered in Watertown, US

Chairman

Tetraphase Pharmaceuticals has an office in Watertown

Watertown, US (HQ)

110 480 Arsenal St

Tetraphase Pharmaceuticals's revenue was reported to be $5.1 m in 2016 which is a **56% decrease** from the previous period.

Numbers are in $, USD

## Revenue (Y, 2016) | 5.1 m |

## Revenue growth (Y, 2015 - Y, 2016), % | (56%) |

## Net income (Y, 2016) | (77.5 m) |

## EBIT (Y, 2016) | (77.8 m) |

## Market capitalization (22-Jun-2017) | 299.1 m |

## Closing share price (22-Jun-2017) | 8 |

## Cash (31-Dec-2016) | 142.1 m |

Tetraphase Pharmaceuticals's current market capitalization is $299.1 m.

Numbers are in $, USD | FY, 2013^{} | FY, 2014^{} | Y, 2015^{} | Y, 2016^{} |
---|---|---|---|---|

## Revenue | 18.3 m | 9.1 m | 11.7 m | 5.1 m |

## Revenue growth, % | (50%) | 28% | (56%) | |

## Operating expense total | 131.1 m | 74.9 m | 94.7 m | 83 m |

## EBIT | (112.8 m) | (65.8 m) | (83 m) | (77.8 m) |

## EBIT margin, % | (617%) | (723%) | (710%) | (1513%) |

## Interest expense | 1.7 m | 1 m | 231 k | 231 k |

## Interest income | 10 k | 17 k | 42 k | 350 k |

## Net Income | (119.7 m) | (66.7 m) | (83.2 m) | (77.5 m) |

Numbers are in $, USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 102.7 m | 121 m | 205.9 m | 142.1 m |

## Accounts Receivable | 1.7 m | 3.5 m | 4.2 m | 1.8 m |

## Inventories | 1 m | 2.1 m | 3.7 m | 6.6 m |

## Current Assets | 105.4 m | 126.6 m | 213.8 m | 150.5 m |

## PP&E | 235 k | 300 k | 943 k | 1.1 m |

## Total Assets | 105.9 m | 127.2 m | 214.9 m | 151.7 m |

## Accounts Payable | 1.9 m | 4.1 m | 2.9 m | 2.6 m |

## Current Liabilities | 13.2 m | 17.3 m | 10.7 m | 11.5 m |

## Additional Paid-in Capital | 207.5 m | 295 m | 473.7 m | 487.1 m |

## Retained Earnings | (186.5 m) | (269.7 m) | (347.1 m) | |

## Total Equity | 87.8 m | 108.6 m | 204.1 m | 140.1 m |

## Financial Leverage | 1.2 x | 1.2 x | 1.1 x | 1.1 x |

Numbers are in $, USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (29.6 m) | (66.7 m) | (83.2 m) | (77.5 m) |

## Depreciation and Amortization | 129 k | 124 k | 193 k | 282 k |

## Accounts Receivable | 746 k | (1.8 m) | (693 k) | 2.4 m |

## Inventories | (154 k) | (1.2 m) | (1.5 m) | |

## Accounts Payable | 310 k | 2.2 m | (1.2 m) | (302 k) |

## Cash From Operating Activities | (24.5 m) | (57.6 m) | (76.7 m) | (63.8 m) |

## Purchases of PP&E | (129 k) | (191 k) | (838 k) | (393 k) |

## Cash From Investing Activities | (129 k) | (191 k) | (838 k) | (393 k) |

## Cash From Financing Activities | 118.3 m | 76.1 m | 162.4 m | 333 k |

## Interest Paid | 1.1 m | 945 k | 363 k | 363 k |

Y, 2016 | |
---|---|

## Financial Leverage | 1.1 x |